- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05092919
The Effect of Sweet Flavoring on the Rewarding and Reinforcing Value of Cigarillo Use Among Young Adults (FLAV)
April 29, 2024 updated by: Janet Audrain-McGovern, University of Pennsylvania
This within-subjects study aims to evaluate the subjective rewarding value, the relative reinforcing value, and the absolute reinforcing value of sweet flavored cigarillos across three separate laboratory visits among 86 young adults (ages 18-24 years old) who have previously smoked > 10 or more cigarillos in their lifetime.
Study Overview
Study Type
Interventional
Enrollment (Actual)
95
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 24 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Able to communicate fluently in English (i.e. speaking, writing, and reading).
- Male and female young adults who are between 18 and 24 years of age who have used > 10 cigarillos in their lifetime.
- Not currently undergoing smoking cessation treatment or planning to quit smoking cigarettes within the next 30 days.
- Plan to live in the area for the duration of the study.
- Willing to use study-provided cigarillos during three laboratory visits.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form.
Exclusion Criteria:
Smoking Behavior
- Use of less than 10 cigarillos in lifetime
- Current enrollment or plans to enroll in a tobacco cessation program over the duration of the study.
- Current use of nicotine replacement therapy or other smoking cessation medication.
Alcohol and Drug
- History of substance abuse (other than nicotine dependence) in the past 12 months and/or currently receiving medical treatment for substance abuse. Counseling and support groups (e.g. Alcoholics Anonymous and Narcotics Anonymous) will not be considered medical treatment for the purposes of this protocol.
- Current alcohol consumption that exceeds 25 standard drinks/week.
- Breath alcohol reading (BrAC) greater than .000 at Laboratory Visit 1.
- Use of e-cigarettes on >5 days in the past 30 days.
Medical
- Women, including all individuals assigned as "female" at birth, who are pregnant, breast feeding, or planning a pregnancy over the duration of the study period.
- Serious or unstable disease within the past year (e.g. cancer, heart disease). Applicable conditions will be evaluated on a case-by-case basis by the Principal Investigator.
Psychiatric
- Lifetime history of schizophrenia or psychosis
- Lifetime history of a suicide attempt.
Current use of medications used to treat mood, such as depression or anxiety.
- Individuals will be excluded if they take psychotropic medications that may impact laboratory assessments of nicotine/flavoring reward and reinforcement.
- Participants with a history of depression or anxiety will not be excluded- however, participants who are currently taking any medications used to treat these will be ineligible to participate.
- Participants who are not currently taking these medications but are receiving treatment such as therapy or counseling will be eligible to participate.
- Current or recent use of anti-psychotic medications.
General Exclusion
- Past, current, anticipated, or pending enrollment in another research program over the study period that could potentially impact subject safety, study data, and/or the study design as determined by the Principal Investigator.
- Any medical condition, illness, disorder, adverse event (AE), or concomitant medication that could compromise participant safety or significantly impact study performance as determined by the Principal Investigator. Subjects may be deemed ineligible for any of the aforementioned reasons at any point throughout the study, as well as during the initial telephone screen.
- Significant non-compliance with protocol and/or study design as determined by the Principal Investigator. Subjects may be deemed ineligible at any point throughout the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Flavor
Either a sweet-flavored or a non-flavored cigarillo
|
Sweet flavored vs. non-flavored cigarillos.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subjective Rewarding Value of Cigarillo Flavoring
Time Frame: Laboratory visit 1 (Day 1, 1.5 hours)
|
Subjective rewarding value of cigarillo flavoring will be measured with the Cigarette Evaluation Scale (CES) adapted for cigarillo use.
The CES is an 11 item Likert-format (1=not at all to 7=extremely) self-report instrument with established validity and reliability (α > .80).
The investigators will focus on the sum of the two-item satisfaction subscale ("Was it satisfying?" and "Did it taste good?") to calculate the subjective rewarding value.
The minimum possible score is 2 and the maximum is 14.
Higher scores denote greater subjective rewarding value.
Primary Outcome measured at visit 1.
|
Laboratory visit 1 (Day 1, 1.5 hours)
|
|
Relative Reinforcing Value of Cigarillo Flavoring
Time Frame: Laboratory visit 2 (Day 2, 2 hours)
|
Relative reinforcing value of cigarillo flavoring will be measured with a validated choice paradigm, evaluating the preference for sweet flavored (the cigarillo with the highest rewarding value measured in visit 1) relative to non-flavored cigarillos.
The reinforcement schedule in the non-flavored cigarillo remained constant at a fixed ratio FR-25, while the reinforcement schedule for the sweet-flavored cigarillo increased with a progressive ratio schedule of PR-25x over 10 trials.
RRVF will be defined by the breakpoint (highest trial completed across 10 trials to earn puffs for sweet flavored versus non-flavored cigarillos).
Higher breakpoints indicate a greater relative reinforcing value.
Primary Outcome measured at visit 2.
|
Laboratory visit 2 (Day 2, 2 hours)
|
|
Absolute Reinforcing Value of Cigarillo Flavoring
Time Frame: Laboratory visit 3 (Day 3, 2.5 hours)
|
Absolute reinforcing value of cigarillo flavoring is operationalized as the number of sweet flavored versus non-flavored cigarillo puffs consumed during the ad libitum smoking session.
A research assistant will videotape, monitor, and count the number of cigarillo puffs taken during the 90-minute period.
The primary comparison is the amount of consumption (puffs) of the sweet flavored (determined at visit 1) versus non-flavored cigarillo.
A greater number of puffs indicates a higher absolute reinforcing value.
Primary Outcome measured at visit 3.
|
Laboratory visit 3 (Day 3, 2.5 hours)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 14, 2021
Primary Completion (Actual)
February 28, 2023
Study Completion (Actual)
May 31, 2023
Study Registration Dates
First Submitted
September 30, 2021
First Submitted That Met QC Criteria
October 12, 2021
First Posted (Actual)
October 26, 2021
Study Record Updates
Last Update Posted (Actual)
May 17, 2024
Last Update Submitted That Met QC Criteria
April 29, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- 843944
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Use
-
Loma Linda UniversityUniversity of California, San Francisco; Riverside University Health System...RecruitingTobacco Use | Tobacco Use Cessation | Tobacco Use in ChildbirthUnited States
-
University of Mississippi Medical CenterNot yet recruitingTobacco Cessation
-
University of California, San FranciscoTobacco Related Disease Research ProgramRecruitingTobacco Cessation | Tobacco Use | Tobacco Use Cessation | Tobacco Dependence | Tobacco AbstinenceUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Duke UniversityCompletedSmokeless Tobacco CessationUnited States
-
University of FloridaRecruitingTobacco Use | Nicotine UseUnited States
-
Harvard School of Public Health (HSPH)Boston University; Dana-Farber Cancer Institute; Dimagi Inc.; Narotam Sekhsaria...Completed
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
Clinical Trials on Flavor
-
Fontem US LLCFontem Ventures BVCompletedHealthy VolunteersUnited States
-
Virginia Polytechnic Institute and State UniversityNational Cancer Institute (NCI); University of MinnesotaCompletedTobacco Use DisorderUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA)CompletedCigarette Smoking | Sex Differences | Nicotine Addiction | E-Cig UseUnited States
-
Federico II UniversityCompletedSmoking | Age Problem | Weight, Body
-
Monell Chemical Senses CenterHVMN (funding; holder of primary Department of Defense STTR contract)CompletedFlavor Perception in Normal, Healthy AdultsUnited States
-
Prisma Health-UpstateNational Institute on Drug Abuse (NIDA)RecruitingOpioid Use Disorder | Nicotine Use DisoderUnited States
-
Monell Chemical Senses CenterNIAID, Division of AIDS (contract funder); Advanced Biosciences Laboratories...RecruitingHealthy AdultsUnited States
-
PepsiCo Global R&DRecruitingFluid BalanceUnited States
-
Cheerain HK LimitedCompletedElectronic Cigarette UseUnited States
-
Penn State UniversityCompleted